vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Star Equity Holdings, Inc. (STRR). Click either name above to swap in a different company.

Star Equity Holdings, Inc. is the larger business by last-quarter revenue ($56.8M vs $37.2M, roughly 1.5× GYRE THERAPEUTICS, INC.). Star Equity Holdings, Inc. runs the higher net margin — -3.0% vs -3.7%, a 0.7% gap on every dollar of revenue. On growth, Star Equity Holdings, Inc. posted the faster year-over-year revenue change (69.0% vs 33.4%). GYRE THERAPEUTICS, INC. produced more free cash flow last quarter ($-5.8M vs $-9.0M). Over the past eight quarters, Star Equity Holdings, Inc.'s revenue compounded faster (29.5% CAGR vs 17.0%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

Artists Equity is an American production company founded by actors and filmmakers Ben Affleck and Matt Damon in November 2022.

GYRE vs STRR — Head-to-Head

Bigger by revenue
STRR
STRR
1.5× larger
STRR
$56.8M
$37.2M
GYRE
Growing faster (revenue YoY)
STRR
STRR
+35.6% gap
STRR
69.0%
33.4%
GYRE
Higher net margin
STRR
STRR
0.7% more per $
STRR
-3.0%
-3.7%
GYRE
More free cash flow
GYRE
GYRE
$3.2M more FCF
GYRE
$-5.8M
$-9.0M
STRR
Faster 2-yr revenue CAGR
STRR
STRR
Annualised
STRR
29.5%
17.0%
GYRE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GYRE
GYRE
STRR
STRR
Revenue
$37.2M
$56.8M
Net Profit
$-1.4M
$-1.7M
Gross Margin
95.3%
Operating Margin
0.3%
-0.2%
Net Margin
-3.7%
-3.0%
Revenue YoY
33.4%
69.0%
Net Profit YoY
-340.1%
-192.1%
EPS (diluted)
$-0.01
$-0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
STRR
STRR
Q4 25
$37.2M
$56.8M
Q3 25
$30.6M
$48.0M
Q2 25
$26.8M
$35.5M
Q1 25
$22.1M
$31.9M
Q4 24
$27.9M
$33.6M
Q3 24
$25.5M
$36.9M
Q2 24
$25.2M
$35.7M
Q1 24
$27.2M
$33.9M
Net Profit
GYRE
GYRE
STRR
STRR
Q4 25
$-1.4M
$-1.7M
Q3 25
$5.9M
$-1.8M
Q2 25
$1.6M
$-688.0K
Q1 25
$3.7M
$-1.8M
Q4 24
$569.0K
$-585.0K
Q3 24
$2.9M
$-846.0K
Q2 24
$4.5M
$-441.0K
Q1 24
$9.9M
$-2.9M
Gross Margin
GYRE
GYRE
STRR
STRR
Q4 25
95.3%
Q3 25
94.7%
43.0%
Q2 25
95.7%
Q1 25
95.9%
Q4 24
95.8%
Q3 24
96.2%
50.5%
Q2 24
96.9%
Q1 24
96.4%
Operating Margin
GYRE
GYRE
STRR
STRR
Q4 25
0.3%
-0.2%
Q3 25
22.7%
-3.4%
Q2 25
8.1%
-0.6%
Q1 25
10.3%
-5.4%
Q4 24
2.4%
-0.4%
Q3 24
16.6%
-1.2%
Q2 24
12.7%
-0.5%
Q1 24
29.7%
-9.0%
Net Margin
GYRE
GYRE
STRR
STRR
Q4 25
-3.7%
-3.0%
Q3 25
19.4%
-3.7%
Q2 25
5.9%
-1.9%
Q1 25
16.9%
-5.5%
Q4 24
2.0%
-1.7%
Q3 24
11.2%
-2.3%
Q2 24
18.0%
-1.2%
Q1 24
36.6%
-8.6%
EPS (diluted)
GYRE
GYRE
STRR
STRR
Q4 25
$-0.01
$-0.49
Q3 25
$0.03
$-0.54
Q2 25
$0.00
$-0.23
Q1 25
$0.00
$-0.59
Q4 24
$0.00
$-0.21
Q3 24
$0.01
$-0.28
Q2 24
$0.01
$-0.15
Q1 24
$0.03
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
STRR
STRR
Cash + ST InvestmentsLiquidity on hand
$52.4M
$10.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$106.0M
$65.7M
Total Assets
$166.1M
$113.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
STRR
STRR
Q4 25
$52.4M
$10.3M
Q3 25
$60.0M
$15.4M
Q2 25
$54.4M
$16.8M
Q1 25
$29.9M
$16.6M
Q4 24
$26.7M
$17.0M
Q3 24
$25.1M
$15.8M
Q2 24
$25.1M
$14.7M
Q1 24
$37.4M
$20.4M
Total Debt
GYRE
GYRE
STRR
STRR
Q4 25
Q3 25
$6.5M
Q2 25
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
GYRE
GYRE
STRR
STRR
Q4 25
$106.0M
$65.7M
Q3 25
$101.9M
$67.8M
Q2 25
$92.0M
$40.1M
Q1 25
$68.1M
$39.5M
Q4 24
$63.3M
$40.4M
Q3 24
$63.2M
$42.9M
Q2 24
$60.4M
$42.6M
Q1 24
$56.6M
$44.3M
Total Assets
GYRE
GYRE
STRR
STRR
Q4 25
$166.1M
$113.2M
Q3 25
$159.4M
$117.1M
Q2 25
$152.6M
$55.6M
Q1 25
$129.8M
$53.2M
Q4 24
$125.4M
$52.6M
Q3 24
$125.2M
$52.6M
Q2 24
$120.9M
$52.6M
Q1 24
$122.0M
$52.6M
Debt / Equity
GYRE
GYRE
STRR
STRR
Q4 25
Q3 25
0.10×
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
STRR
STRR
Operating Cash FlowLast quarter
$-5.6M
$-7.3M
Free Cash FlowOCF − Capex
$-5.8M
$-9.0M
FCF MarginFCF / Revenue
-15.5%
-15.8%
Capex IntensityCapex / Revenue
0.4%
3.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-180.0K
$-13.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
STRR
STRR
Q4 25
$-5.6M
$-7.3M
Q3 25
$4.7M
$-2.7M
Q2 25
$2.1M
$139.0K
Q1 25
$-129.0K
$-802.0K
Q4 24
$-2.8M
$-2.8M
Q3 24
$1.7M
$1.3M
Q2 24
$-5.5M
$-4.3M
Q1 24
$2.9M
$-1.8M
Free Cash Flow
GYRE
GYRE
STRR
STRR
Q4 25
$-5.8M
$-9.0M
Q3 25
$4.0M
$-3.4M
Q2 25
$1.8M
$102.0K
Q1 25
$-251.0K
$-808.0K
Q4 24
$-2.8M
$-2.8M
Q3 24
$1.0M
$1.3M
Q2 24
$-6.9M
$-4.3M
Q1 24
$2.7M
$-1.8M
FCF Margin
GYRE
GYRE
STRR
STRR
Q4 25
-15.5%
-15.8%
Q3 25
13.1%
-7.0%
Q2 25
6.8%
0.3%
Q1 25
-1.1%
-2.5%
Q4 24
-10.1%
-8.3%
Q3 24
4.1%
3.4%
Q2 24
-27.5%
-12.0%
Q1 24
9.8%
-5.3%
Capex Intensity
GYRE
GYRE
STRR
STRR
Q4 25
0.4%
3.0%
Q3 25
2.2%
1.3%
Q2 25
1.0%
0.1%
Q1 25
0.6%
0.0%
Q4 24
0.2%
0.1%
Q3 24
2.7%
0.0%
Q2 24
5.8%
0.0%
Q1 24
0.9%
0.0%
Cash Conversion
GYRE
GYRE
STRR
STRR
Q4 25
Q3 25
0.79×
Q2 25
1.32×
Q1 25
-0.03×
Q4 24
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GYRE
GYRE

Segment breakdown not available.

STRR
STRR

Revenue From Other Contracts With Customers$27.6M49%
Other$24.3M43%
Energy Services Segment$4.9M9%

Related Comparisons